Xin Lin is an NP in the urology department and Stacie Corcoran is program director of adult cancer survivorship, both at Memorial Sloan Kettering Cancer Center, New York City. Contact author: Xin Lin,
Am J Nurs. 2019 Feb;119(2):32-41. doi: 10.1097/01.NAJ.0000553181.82330.d4.
: Hodgkin lymphoma (HL) is a highly curable cancer. Advances in diagnosis and treatment have resulted in excellent cure rates, producing an ever-increasing number of HL survivors who live decades beyond their initial cancer treatment. These survivors, however, are at risk for late effects secondary to the cancer treatments they received years earlier, most notably, subsequent primary cancers, cardiovascular disease, pulmonary toxicity, and endocrine dysfunction. Monitoring and managing such late treatment effects may significantly challenge survivors' long-term health care providers, who may need to take on increased survivorship care. For physicians and nurses working outside of oncology settings, who are increasingly called upon to collaborate with oncologists when caring for HL survivors, understanding the late treatment effects and potential risk factors facing this growing patient population is essential to the provision of comprehensive long-term care. The authors provide an overview of HL, review the most commonly encountered late adverse effects of treatment, and discuss current recommendations for survivor surveillance and screening.
霍奇金淋巴瘤(HL)是一种高度可治愈的癌症。诊断和治疗方面的进步带来了出色的治愈率,使越来越多的 HL 幸存者在初始癌症治疗后存活数十年。然而,这些幸存者存在因多年前接受的癌症治疗而导致的晚期效应的风险,最常见的是继发原发性癌症、心血管疾病、肺毒性和内分泌功能障碍。监测和管理这些晚期治疗效果可能会对幸存者的长期医疗保健提供者构成重大挑战,他们可能需要承担更多的生存者护理工作。对于在肿瘤学治疗环境之外工作的医生和护士来说,他们越来越多地被要求在照顾 HL 幸存者时与肿瘤学家合作,了解这一不断增长的患者群体所面临的晚期治疗效果和潜在风险因素对于提供全面的长期护理至关重要。作者概述了 HL,回顾了治疗中最常见的晚期不良反应,并讨论了目前对幸存者监测和筛查的建议。